Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-01-05
DOI
10.3389/fonc.2022.1007146
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
- (2022) Keun-Wook Lee et al. CLINICAL CANCER RESEARCH
- The impact of recent next generation sequencing and the need for a new classification in gastric cancer
- (2021) Gianluca Businello et al. Best Practice & Research Clinical Gastroenterology
- Current treatment and recent progress in gastric cancer
- (2021) Smita S. Joshi et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia
- (2021) Deqiang Wang et al. Gastric Cancer
- LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
- (2021) Landon C Brown et al. Journal for ImmunoTherapy of Cancer
- Cancer statistics for the year 2020: An overview
- (2021) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy
- (2021) Adrian Kwan Ho Loe et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
- (2021) Timothy A Yap et al. Lancet Respiratory Medicine
- The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer
- (2021) Juan Sun et al. Frontiers in Oncology
- FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
- (2021) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- (2021) Yelena Y Janjigian et al. LANCET
- The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance
- (2021) Kangchen Chen et al. Cell Death & Disease
- Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy
- (2020) Tong Xie et al. JOURNAL OF IMMUNOTHERAPY
- Prognostic impact of gene copy number instability and tumor mutation burden in patients with resectable gastric cancer
- (2020) Lisheng Cai et al. Cancer Communications
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
- (2020) Chen Lin et al. Frontiers in Oncology
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Prognostic Value of Serum Soluble Programmed Death-Ligand 1(sPDL1) and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
- (2020) Woochan Park et al. Cancer Research and Treatment
- DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
- (2020) Changzheng Lu et al. CANCER CELL
- First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
- (2019) Neal Ready et al. JOURNAL OF CLINICAL ONCOLOGY
- Bridging genomics and phenomics of gastric carcinoma
- (2019) Junhun Cho et al. INTERNATIONAL JOURNAL OF CANCER
- DNA Damage Response and Repair Pathway Alteration and Its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in Small Cell Lung Cancer
- (2019) Sehhoon Park et al. Journal of Thoracic Oncology
- Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018
- (2019) Faisal Shahjehan et al. Frontiers in Oncology
- Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
- (2019) F Wang et al. ANNALS OF ONCOLOGY
- Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
- (2019) Martin Reck et al. EUROPEAN JOURNAL OF CANCER
- Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
- (2019) Jiaxin Zhu et al. Frontiers in Pharmacology
- Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
- (2019) Hao Chen et al. Frontiers in Immunology
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
- (2019) Aparna R. Parikh et al. NATURE MEDICINE
- Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
- (2019) Samuel J. Klempner et al. ONCOLOGIST
- The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
- (2019) Yongfeng Wu et al. Frontiers in Oncology
- What’s New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives
- (2018) Giuseppe Tirino et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy
- (2017) Xiaohong Wu et al. Future Oncology
- Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer
- (2017) Xiaowei Mao et al. Journal of Thoracic Oncology
- Lung Cancer: Frontline nivolumab — CheckMate 026 ends in stalemate
- (2017) David Killock Nature Reviews Clinical Oncology
- Future perspectives of circulating tumor DNA in colorectal cancer
- (2017) C Nadal et al. TUMOR BIOLOGY
- Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
- (2016) Carles Pericay et al. Cancer Medicine
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Management of gastric cancer
- (2014) Geoffrey Y. Ku et al. CURRENT OPINION IN GASTROENTEROLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis
- (2013) Y. Touil et al. CLINICAL CANCER RESEARCH
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started